Physician profile
Beth Ann Devine
NPI 1679670202
$5,977.69
in general payments reported to CMS, 2019-2025
30 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $946 · 2023: $905 · 2024: $1,759 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.02 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.44 | 2021-2025 | |
| Corium, LLC | $672.15 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.80 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $553.17 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $368.45 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $341.75 | 2023-2024 | Qelbree, Qelbree |
| Novo Nordisk INC | $327.67 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Alkermes, INC. | $271.41 | 2022-2025 | Lybalvi |
| Astrazeneca Pharmaceuticals Lp | $236.61 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $143.68 | 2024-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $129.25 | 2022-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Viiv Healthcare Company | $107.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $89.66 | 2022-2025 | Cobenfy |
| Baxter Healthcare | $75.71 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $69.88 | 2025 | Senza |
| Sunovion Pharmaceuticals INC. | $57.30 | 2022 | |
| Lundbeck LLC | $57.28 | 2022-2024 | Rexulti |
| Pfizer INC. | $53.99 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $48.03 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $47.00 | 2022-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Amarin Pharma, INC. | $17.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.18 | 2023 | |
| Neurocrine Biosciences, INC. | $16.01 | 2025 | |
| Exact Sciences Corporation | $15.66 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $14.73 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.35 | 2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $13.87 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $13.82 | 2023 | Quviviq |
| Dexcom, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.